New Linshom Patient Survey Reveals Gaps on the Path to Severe Asthma Treatment

The treatment exists, but the road to it is not always simple: almost 3 in 10 waited more than four months, health fund approval stood out as the main point of delay, and for some patients the cost also affects their ability to continue treatment. Linshom's survey presents patients' gaps, needs and priorities along the entire journey.

The survey was sponsored by AstraZeneca, with no involvement in the content.

Biologic treatments have significantly changed the treatment options for severe asthma. For patients they suit, they can reduce flare-ups, and for some patients they can also improve disease control and quality of life and reduce the need for steroids.

But the medical option is only part of the journey.

A survey Linshom conducted among the asthma community examined the journey from the patients' point of view: how much time passes from the doctor's recommendation to the start of treatment, what causes delays along the way, whether cost affects the ability to continue treatment, what information and support patients receive, and what matters to them in the treatment itself.

The answers paint a picture of barriers that appear at different points along the journey. On the way to starting treatment, health fund approval stands out as the main point of delay that patients report. Once treatment has already started, some respondents face a different barrier: cost and co-payments, which can affect their ability to stick with treatment.

At the same time, patients themselves set clear priorities: fewer attacks and symptoms, less steroid use and better day-to-day functioning matter more to them than convenient treatment frequency.

What Has Changed in Severe Asthma Treatment?

Severe asthma is asthma that remains uncontrolled despite optimal high-intensity treatment, after factors that can affect disease control have been checked.

Biologic treatments are targeted treatments that act on specific pathways involved in the inflammatory process in asthma. They are not meant for every person with asthma, and suitability is determined by the characteristics of the disease and the patient.

Their introduction has significantly changed the treatment options for severe asthma. For suitable patients they can reduce flare-ups, and for some patients they can also improve disease control and quality of life and reduce the need for steroids.

In Israel, certain biologic treatments for severe asthma are included in the health basket (the national list of publicly funded treatments), subject to defined medical criteria.

Linshom's survey was not designed to examine which biologic treatment is better. We wanted to understand something else: what does the road to treatment, and beyond it, look like through the eyes of patients themselves?

The Recommendation Was Given, but for Some the Road to the First Injection Took Months

One of the survey's most striking findings concerns the time between the doctor's recommendation of biologic treatment and the actual start of treatment.

47% of patients who started treatment reported receiving their first injection within a month of the doctor's recommendation. 16% waited between one and two months. 8% waited between two and four months. 29% waited more than four months.

The differences between patients are large. For some, the medical recommendation turns into treatment within weeks. For others, months go by before treatment begins.

And when we asked which stage delayed them the most, the answer was clear.

Health Fund Approval Stands Out as the Main Point of Delay

53% of patients who started treatment marked the time it took to get approval from their health fund as the stage that delayed them the most. 32% said they experienced no delay and received treatment right away. 11% mentioned a delay in scheduling training for the first injection. 5% mentioned a delay in ordering or receiving the medication.

The link grows stronger when looking at patients who waited especially long. Among those who reported waiting more than four months, 82% marked health fund approval as the most delaying stage.

In other words, the survey does not only show that some patients wait months. It also clearly points to the stage where, according to their reports, a significant part of the delay is concentrated.

The survey does not detail what within the approval process caused the wait in each case. It cannot tell us whether it was missing documents, eligibility conditions, additional tests, an administrative process or another reason.

But when it comes to the question of at which stage patients experience the delay, health fund approval stands out above all other stages.

Treatment Has Started, but for Some Patients the Cost Makes It Hard to Continue

Difficulty accessing treatment does not necessarily end once approval has been received and the first injection given.

Among those who answered the question about financial considerations, 25% said cost affects their ability to stay on biologic treatment.

When we asked how cost affects them, high co-payments were the most frequently mentioned reason.

Some respondents also explicitly reported stopping treatment because they could not afford the cost, and another respondent mentioned, alongside high co-payments, that their health fund had not approved the medication.

Cross-checking the answers adds important context: financial difficulty also appeared among patients who did not report a delay in starting treatment. In other words, it is not necessarily the same barrier.

The survey reveals two different points along the journey.

Before treatment starts, for some patients the difficulty is actually getting to treatment, with health fund approval standing out as the most delaying stage.

Once treatment has started, for some respondents cost and co-payments can become a barrier to continuing treatment without interruption.

The survey does not allow us to determine the source of the cost in each case. It does not distinguish between co-payments within eligibility, treatment that was not approved, treatment that does not meet the health basket's conditions, or other situations. Therefore, it should not be concluded from it that any particular treatment is not included in the health basket.

But it does point to a meaningful phenomenon: for some of the patients who answered the survey, financial difficulty is not just an inconvenience. It can actually affect their ability to continue treatment.

What Matters to Patients? Results Before Convenience

We asked patients to rate how important various features of treatment are to them. This produced one of the clearest pictures in the survey.

95% gave the highest importance score to reducing asthma attacks. 95% gave the highest score to reducing symptoms. 94% gave the highest score to improving quality of life and daily functioning. 93% gave the highest score to reducing or stopping steroid use.

By comparison, 77% gave the highest score to fewer side effects. 67% gave the highest score to convenient treatment frequency.

The data do not mean that treatment convenience is unimportant. They do show that when patients define what matters most to them, the results treatment should achieve in everyday life take higher priority than convenient frequency.

Most Patients Received a Medical Explanation, Yet Many Kept Looking for Information

61% of patients who started treatment reported that before seeing their doctor, they had not yet heard of biologic treatments for severe asthma.

On its own, this figure does not indicate a gap. For many patients, it is natural for an advanced treatment option to come up in a conversation with a doctor.

What is interesting is what happened next.

76% searched for information about the treatment on their own.

Among those who searched for information, 72% used a general internet search, 41% turned to Facebook groups, 34% asked a doctor or nurse, 21% sought information from other patients and 7% used a nonprofit association's website. More than one source could be chosen.

At the same time, 76% of patients who started treatment said that someone on the medical team explained the treatment to them well.

Among those who received an explanation, a specialist pulmonologist was the main source.

Cross-checking the answers sharpens the picture.

Among those who answered both the question about explanation and the question about missing information, 43% of those who received a good explanation still said they lacked information, compared with 88% of those who did not receive a good explanation.

This should not be taken to mean that the explanation alone accounts for the gap.

The finding does show that among those who received a good explanation, the rate of those reporting missing information was much lower.

The picture is not one of a widespread lack of medical explanation. On the contrary, most respondents reported receiving a good explanation. For some patients, however, questions and missing information remained even after the explanation.

What Information Was Missing Before Starting Treatment?

Among those who answered the question of whether they lacked information before starting treatment, 55% said yes.

Looking only at those who said they lacked information, three topics stood out in particular.

69% wanted more information about side effects. 63% wanted to hear from patients who had already been through the process. 44% wanted information about other treatment options. 19% wanted more explanation about the disease. 13% mentioned the option of getting a second opinion. More than one answer could be chosen.

This finding sharpens the question of information. The question is not only whether the patient knows that biologic treatment exists, but whether they understand what to expect, what options are available to them and what starting treatment means for everyday life.

Fewer Than Half Received Support as Part of Their Treatment

45% of patients who started treatment reported receiving support from a nurse or taking part in a support program as part of their treatment. 55% said they did not receive such support.

Among those who received support, 82% rated their satisfaction with it at 8 or higher out of 10.

The survey does not allow us to conclude that the support itself improved treatment results. It does show that most respondents who received support rated it with high satisfaction.

Even After Treatment Starts, the Need for Information and Support Remains

When we asked in which areas they would like more help or support related to their disease, the picture that emerged was broader than a need for medical information alone.

61% wanted more information about treatment options. 50% wanted answers to personal questions. 39% wanted the chance to talk with people facing a similar situation. 37% wanted emotional support from a professional. 24% wanted support groups. 18% wanted more information about the disease. More than one answer could be chosen.

The answers show that patients' needs do not end with the prescription or the first injection. They also include ongoing information, personal answers, the experience of others and professional support.

Most Patients Report Regular Treatment, but the Degree of Improvement Varies

87% of patients who started biologic treatment reported receiving it regularly. 8% reported intermittent treatment. 5% reported gaps between treatments on their doctor's recommendation.

When asked how much the treatment improved their quality of life, 32% gave a score of 8 to 10, 39% gave a score of 5 to 7 and 29% gave a lower score.

This is a self-assessment of improvement in quality of life, not a clinical measure of treatment effectiveness.

Respondents were also at very different stages of treatment. Some were in their first months, while others had already been treated for a year or more. This distribution should therefore not be used to compare patients or treatments.

Both findings together are important: a large majority report regular treatment, but the experience of improvement is not the same for everyone.

The Path from an Asthma Diagnosis to Severe Asthma Is Not the Same for Everyone

Respondents reached severe asthma along different paths.

Roughly half were diagnosed with asthma in childhood and half in adulthood.

The time from an asthma diagnosis to the understanding that it was severe asthma also varied widely. 26% reported a period of up to six months. 24% reported more than ten years. The remaining respondents reported various periods between these two extremes.

This should not be taken to mean that severe asthma went unrecognized for years.

Cross-referencing the answers shows that most of those who reported a period of more than ten years had already been diagnosed with asthma in childhood.

The survey cannot tell us when the disease became severe, whether its severity changed over the years, or what explains the differences between patients.

So this figure describes variation in the course of the disease, not a proven delay in diagnosis.

What Do Patients Tell Us About the Path to Treatment?

Biologic treatments have significantly expanded the treatment options for severe asthma. But the survey shows that the patient's experience involves much more than the medication itself.

On the way to treatment, nearly 3 in 10 reported waiting more than four months, and health fund (HMO) approval stands out as the main point of delay reported by patients.

Once treatment has started, some respondents face a different barrier: cost. One in four of those who answered the question about finances said it affects their ability to stay on treatment, and some answers also described stopping treatment because of the cost.

When it comes to choosing a treatment, patients say clearly what matters to them: fewer attacks and symptoms, less use of steroids, and better functioning and quality of life.

At the same time, most patients reported receiving a good explanation from the medical team, but many kept looking for information on their own, and some felt they lacked concrete information before starting treatment.

Fewer than half received ongoing support, while most of those who did rated it highly.

And even after treatment has started, patients continue to ask for information, personal answers and support.